Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
"We are thrilled to welcome back Tim Mooney to Kendle's Board," saidChairman and Chief Executive Officer Candace Kendle, PharmD. "Tim played apivotal role in leading Kendle's financial operations during our early yearsas a private and then public company and our emergence as a global provider ofCRO services, and we look forward to having the benefit of his experience withus once again as part of our Board. His extensive background in finance andaccounting and knowledge of our sector will serve us well as Kendle continuesto accelerate its position as a leading provider of Phase I-IV clinicaldevelopment services to biopharmaceutical companies worldwide."
Prior to Kendle, Mooney served as Vice President, Treasurer and ChiefFinancial Officer for The Future Now, Inc. and Senior Vice President and ChiefFinancial Officer for Hook-SupeRx, Inc. His experience also includes servingas a Partner with the public accounting firm Coopers & Lybrand. He currentlyserves on the Board of Directors of Regent Communications, Inc., a publiclytraded radio broadcasting company headquartered in Covington, Ky. He isChairman of Regent's Audit Committee and is a member of the Nominating andCorporate Governance Committee. Mooney also has served on the Board ofDirectors of Winton Financial Corp., and as Chairman of Winton's AuditCommittee and as a member of its Compensation Committee. Mooney earned abachelor of science in business administration from Xavier University inCincinnati.
Mooney's appointment increases the number of Kendle directors from sevento eight and the number of independent directors from five to six. He joinsDr. Kendle and current board members Christopher C. Bergen, Chief OperatingOfficer, Kendle; Robert R. Buck, President and Chief Executive Officer, BeaconRoofing Supply, Inc.; G. Steven Geis, PhD, M.D., Retired, Group VicePresident: Arthritis, Cardiovascular and Oncology Clinical Development,Pharmacia & Upjohn Company; Donald C. Harrison, M.D., Senior Vice Presidentand Provost for Health Affairs Emeritus, University of Cincinnati; Timothy E.Johnson, PhD, President, Johnson Investment Counsel, Inc. and Professor ofFinance, University of Cincinnati; and Frederick A. Russ, PhD, Senior ViceProvost, University of Cincinnati.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinicalresearch organization providing the full range of early- to late-stageclinical development services for the world's biopharmaceutical industry. Ourfocus is on innovative solutions that reduce cycle times for our customers andaccelerate the delivery of life-enhancing drugs to market for the benefit ofpatients worldwide. As one of the fastest-growing global providers of PhaseI-IV services, we offer experience spanning 90 countries, along withindustry-leading patient access and retention capabilities and broadtherapeutic expertise, to meet our customers' clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100fastest-growing companies in the United States for 2008. The company also hasbeen recognized as "Top CRO to Work With" in the Thomson CenterWatch 2007survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leadingglobal pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at http://www.kendle.com.
SOURCE Kendle International Inc.
You May Also Like